ClinicalTrials.gg
CompletedNCT07949253Updated Nov 19, 2026

Does Aerobic Exercise Provide Additional Benefits in the Rehabilitation of Sarcopenic Patients With Rheumatoid Arthritis?

An interventional study of Supervised Resistance Exercise and Aerobic Exercise (Brisk Walking) in Sarcopenia and Rheumatoid Arthritis (RA), sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jan 2024, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 131 studies in Sarcopenia with a site in Turkey — 36 open to participants now, 43 under way, none of them phase 3. Sarcopenia · Turkey.

Enrollment
13th of 34
48 · median 40
Started
2024
with 20 others
No phase
32 of 131
6 open now
Registered
131st of 131
by date
Lead sponsor
9 of 131
Ankara Etlik City Hospital

Among the 131 studies in Sarcopenia with a site in Turkey, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 21 that started in 2024, is one of 32 with no phase, and was the 131st registered.

Sarcopenia

1,333 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 131 studies in Sarcopenia with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 154 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Sarcopenia with a site in Turkey, or all of them as a file.
02

Study summary

Sarcopenia is a common complication of rheumatoid arthritis (RA), and resistance exercise is the main recommended treatment. This study evaluated the prevalence of sarcopenia and its associated factors in RA patients aged 18 to 65 years, and tested whether adding aerobic exercise to resistance exercise provides additional benefit. RA patients were screened for sarcopenia according to EWGSOP2 criteria (handgrip strength, bioelectrical impedance analysis, and 4-meter gait speed). Regional sarcopenia was assessed with ultrasonography using the sonographic thigh adjustment ratio (STAR). Patients with sarcopenia who were eligible for exercise were randomized into two groups for 12 weeks: resistance exercise alone, or resistance exercise plus brisk walking. Muscle strength, muscle mass, physical performance, ultrasonographic muscle thickness, disease activity, function, and quality of life were compared before and after the program.

Read the detailed description

This was a single-center study conducted at the Rheumatologic Diseases Outpatient Clinic of the University of Health Sciences Ankara Etlik City Hospital, Physical Medicine and Rehabilitation Hospital, between January 2024 and April 2025. It had two phases.

Phase 1 was cross-sectional. RA patients aged 18 to 65 years, diagnosed by the 2010 ACR/EULAR criteria, were evaluated for sarcopenia by EWGSOP2 criteria. Handgrip strength was measured with a digital hand dynamometer, muscle mass with bioelectrical impedance analysis, and physical performance with 4-meter gait speed. Anterior thigh and anterior arm muscle thickness were measured by ultrasonography, and STAR was calculated as thigh muscle thickness divided by body mass index.

Phase 2 was a randomized, parallel-group exercise trial. Patients diagnosed with sarcopenia who met the exercise eligibility criteria were randomized by the sealed-envelope method into two groups. Both groups attended supervised group exercise sessions of 60 minutes, twice a week, for 12 weeks. Each session included warm-up, range-of-motion exercises, balance training, progressive resistance exercise, and cool-down. The second group was additionally asked to do 30 minutes of brisk walking at home on two other days each week.

Assessments were repeated at week 12. Outcomes included handgrip strength, skeletal muscle mass, gait speed, ultrasonographic muscle thickness, ESR, CRP, SDAI, pain VAS, HAQ, and RAQoL.

03

Conditions studied

  • Sarcopenia
  • Rheumatoid Arthritis (RA)

Keywords

  • Resistance Exercise
  • Aerobic Exercise
  • Ultrasonography
  • Muscle Strength
  • Handgrip Strength
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria Age 18 to 65 years Sarcopenia diagnosed according to EWGSOP2 criteria Low or remission disease activity (SDAI 11 or below) Normal cognitive function, able to speak and understand Turkish Willing to participate and provide written

Exclusion criteria

Exclusion Criteria:

below 20 or above 40 kg/m² Another inflammatory disease besides rheumatoid arthritis Pregnancy Immobilization for more than 15 days in the last 6 months use in the last 3 months Uncontrolled diabetes mellitus Congestive heart failure Cardiac pacemaker Advanced liver or kidney failure Orthopedic surgery such as amputation or total knee or hip replacement Neurological disease such as cerebellar disease or multiple sclerosis Hand deformity or arthralgia preventing grip strength measurement Lower limb deformity preventing walking Advanced arterial or venous insufficiency, thrombosis, or thrombophlebitis Low trunk or lower limb muscle strength (Medical Research Council grade 3 or below) Poor balance (Berg Balance Scale score below 21)

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Resistance Exercise

    Patients with sarcopenia received the supervised resistance exercise program only.

    Behavioral: Supervised Resistance Exercise

  • Experimental
    Resistance Exercise Plus Aerobic Exercise

    Patients with sarcopenia received the same supervised resistance exercise program plus brisk walking.

    Behavioral: Supervised Resistance Exercise · Behavioral: Aerobic Exercise (Brisk Walking)

Interventions

  • BehavioralSupervised Resistance Exercise

    12 weeks of supervised group exercise, 60 minutes per session, twice a week. Each session includes 5 minutes of warm-up, 10 minutes of range-of-motion exercises, 20 minutes of balance training, 20 minutes of progressive resistance exercise with ankle weights and elastic bands at 60-70% of one-repetition maximum (Borg 11-13), and 5 minutes of cool-down.

  • BehavioralAerobic Exercise (Brisk Walking)

    30 minutes of brisk walking at home on two additional days each week for 12 weeks, with 5 minutes of warm-up and 5 minutes of cool-down, at a Borg score of 11-13. Adherence was checked weekly.

06

What researchers measure

Primary outcomes

  1. Change in handgrip strength

    Dominant and non-dominant handgrip strength measured with a digital hand dynamometer (kg)

    Time frame: Baseline and week 12

  2. Change in skeletal muscle mass index (SSMI)

    Skeletal muscle mass measured by bioelectrical impedance analysis and divided by height squared (kg/m²)

    Time frame: Baseline and week 12

  3. Change in physical performance

    Usual gait speed over 4 meters (m/s)

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change in ultrasonographic anterior thigh muscle thickness

    Thickness of rectus femoris plus vastus intermedius measured by ultrasonography on dominant and non-dominant sides (mm)

    Time frame: Baseline and week 12

  2. Change in ultrasonographic anterior arm muscle thickness

    Thickness of biceps brachii plus brachialis measured by ultrasonography on dominant and non-dominant sides (mm)

    Time frame: Baseline and week 12

  3. Change in sonographic thigh adjustment ratio (STAR)

    Anterior thigh muscle thickness (mm) divided by body mass index (kg/m²)

    Time frame: Baseline and week 12

  4. Change in sarcopenia status

    Sarcopenia classification according to EWGSOP2 criteria

    Time frame: Baseline and week 12

  5. Change in disease activity

    Simplified Disease Activity Index (SDAI)

    Time frame: Baseline and week 12

  6. Change in pain

    Pain on a 0-10 cm visual analog

    Time frame: Baseline and week 12

  7. Change in functional status

    Health Assessment Questionnaire (HAQ), score 0-3, higher is worse

    Time frame: Baseline and week 12

  8. Change in quality of life

    Rheumatoid Arthritis Quality of Life questionnaire (RAQoL), score 0-30, higher is worse

    Time frame: Baseline and week 12

  9. Change in inflammatory markers

    Erythrocyte sedimentation rate (mm/h) and C-reactive protein (mg/L)

    Time frame: Baseline and week 12

07

Study locations

1 site
  • Ankara Etlik City Hospital
    Ankara, 06170, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Apr 2025, 15 months.

Of 495 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's 15 months is below that.

Counting every sponsor, half of 506 studies reached it within 18 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
Jan 1, 2024
Primary completionActual
Apr 1, 2025
CompletionActual
Apr 30, 2025
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07949253
Responsible party
METHİYE KÜBRA SEZER (Specialist Physician, Physical Medicine and Rehabilitation, Ankara Etlik City Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 1, 2024
Primary completion
Apr 1, 2025
Completion
Apr 30, 2025
Last update
Nov 19, 2026

Study contacts

Ajda Bal, MD
principal investigator · University of Health Sciences, Ankara Etlik City Hospital, Physical Medicine and Rehabilitation Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion